The cancer drug developer is set to float on the Nasdaq Global Select Market, presenting an opportunity for strategic investors Pharmaron, Celgene, Amgen and Merck & Co to exit.
Imago BioSciences, a US-based oncology therapy developer backed by contract research organisation Pharmaron and pharmaceutical firms Celgene, Amgen and Merck & Co, has filed for a $100m initial public offering.
Founded in 2012, Imago is working on small molecule drug treatments for serious diseases that affect the bone marrow. Its product candidates target lysine-specific demethylase 1 (LSD1), an enzyme crucial to the production of blood stem cells in the bone marrow.
The company will use the IPO proceeds to advance…
